1)t-PA人组织型纤溶酶原激活剂
1.The plant expressing vectors containing human t-PA gene was constructed and transformed in into agnobacterium GV3101.实验室构建了携带有人组织型纤溶酶原激活剂(tissue plasminogen activator,t-PA)植物表达载体并转化入根瘤农杆菌GV3101。
2.Fusion gene of human tissue-type plasminogen activator(t-PA) and green fluorescent protein(GFP) was inserted into pCAMBI1302 for constructing the plant expressing vector pCA1302NSF-tPA.构建人组织型纤溶酶原激活剂 (t PA)与绿色荧光蛋白 (GFP)融合表达的植物表达载体pCA130 2NSF tPA。
3.To study the apo-tPA fusion gene expression in chicken embryo liver cells in vitro,and to test the content and the biological activity of t-PA,the expression plasmid pCDNA_3-apo-△tPA was construeted and transfected into the chicken embryo liver cells cultured in vitro by Liposome.为了探讨apo-B100介导的t-PA融合蛋白在鸡胚肝细胞中分泌表达的可行性和生物学活性,将编码人组织型纤溶酶原激活剂功能区的基因片段△t-PA与鸡VLDLy组装前体apo-B100进行融合,定向克隆到pCDNA_3表达载体CMV启动子下游,构建pCDNA_3-apo-ΔtPA表达载体。
英文短句/例句
1.Establishment of Transgenic Goats for Human Tissue-type Plasminogen Activator with Sperm Mediated Gene Transfer Method;利用精子载体方法研制人组织型纤溶酶原激活剂突变体转基因羊乳腺生物反应器
2.Construction of Bacterial Artificial Chromosome Vectors Containing Human Tissue-type Plasminogen Activator Mutant Gene Specially Expressed in Mammary Gland with Red Recombination System;利用Red系统构建人组织型纤溶酶原激活剂突变体BAC乳腺特异表达载体
3.Comparison of Recombinant Tissue Plasminogen Activator, Urokinase and Defibrase in Vitro Simulation of Thrombolytic Test重组织型纤溶酶原激活剂、尿激酶和降纤酶体外溶栓效果比较
4.Clinical Study of the Expression of Tissue Factor and Urokinase Plasminogen Activator Receptor in Breast Cancer组织因子、尿激酶型纤溶酶原激活剂受体在乳腺癌中的表达
5.Evaluation of the therapeutic effect of thrombolytic therapy with rt-PA and nursing intervention in patients with acute myocardial infarction急性心肌梗死重组组织型纤溶酶原激活剂溶栓治疗的观察及护理
6.Therapeutic effect observation of thrombolysis with rt-PA intravenous in recurrent cerebral infarction重组组织型纤溶酶原激活剂对再发性脑梗死静脉溶栓治疗评价
7.Therapeutic Effect of Ultra Earlier Thrombolysis of Recombinant Tissue Plasminogen Activator in Acute Cerebral Infarction重组组织型纤溶酶原激活剂超早期溶栓治疗急性脑梗死的疗效
8.Thrombolytic therapy with intravenous recombinant tissue plasminogen activator for acute cerebral infarction重组组织型纤溶酶原激活剂静脉溶栓治疗急性脑梗死19例
9.Study on Recombinant Nonglycosylated Urokinase-type Plasminogen Activator;重组非糖基化尿激酶型纤溶酶原激活剂的研究
10.The Recombinant Human Tissue-type Plasminogen Activator in the Treatment of Deep Venous Thrombosis of the Lower Extremities重组组织型纤溶酶原激活剂治疗下肢深静脉血栓形成的临床应用
11.Experimental study on prevention of the peritoneal adhesion by recombinant tissue-type plasminogen activator on rats重组组织型纤溶酶原激活剂预防大鼠腹腔粘连的实验研究
12.Therapeutic effect evaluation of recombinant tissue plasminogen activator in hyper acute cerebral infarction重组组织型纤溶酶原激活剂治疗急性脑梗死的疗效评价
13.Construction of Tissue-type Plasminogen Activator Variants and Their Expression in Prokaryotic and Eukaryotic Cells;组织型纤溶酶原激活剂（t-PA）突变体的构建及其表达研究
14.Construction of Eukaryotic Expessing Vector of Tissue Plasminogen Activator (t-PA);组织型纤溶酶原激活剂（t-PA）真核表达载体的构建
15.Advances in the Study of Tissue-type Plasminogen Activator and Its Toxicity in the Central Nervous System;组织型纤溶酶原激活剂与中枢神经系统毒性的研究进展
16.Construction of Tissue Plasminogen Activator-annexin A5 Fusion Gene组织型纤溶酶原激活剂—膜联蛋白A5融合基因的构建
17.DETERMINATION OF THE PLASMINOGEN ACTIVATOR IN THE TONSIL OF CHRONIC TONSILLITIS慢性扁桃体炎组织中的纤溶酶原激活剂测定
18.Comparative study on intravenous rt-PA and uroninase thrombolytic strategy for acute myocardial infarction重组组织型纤溶酶原激活剂与尿激酶静脉内溶栓治疗急性心肌梗死的比较研究
相关短句/例句
tissue-type plasminogen activator组织型纤溶酶原激活剂
1.Expression of human tissue-type plasminogen activator in cow mammary gland;人组织型纤溶酶原激活剂牛乳腺生物反应器的研究
2.Studies on thrombolysis of recombinant human tissue-type plasminogen activator(rht-PA)and its mutants;重组人组织型纤溶酶原激活剂及其突变体的溶血栓研究
3.Trichoderma reesei 306 was a recombinant strain that can produce tissue-type plasminogen activator(t-PA).里氏木霉(Trichoderma reesei)306是能够生物合成组织型纤溶酶原激活剂(t-PA)的基因工程菌株。
3)tPA组织型纤溶酶原激活剂
1.Expression of tPAcDNA Gene in BHK 21 Cell;组织型纤溶酶原激活剂cDNA在BHK21细胞中的表达
2.The Expression of tPA Directed by the Bovine BLG Regulatory Elements in the Mammary Gland of Transgenic Mice;牛β-乳球蛋白基因调控序列指导组织型纤溶酶原激活剂在小鼠乳腺中的表达
3.From the point of view of large-scale and rapid purification of tPA, a variety of methods for the purification of tPA and the separation of single-chain and two-chain tPA were reviewed.简述了用于大规模生产组织型纤溶酶原激活剂(tPA)的重组动物细胞及其培养工艺。
4)tissue plasminogen activator组织型纤溶酶原激活剂
1.Construction of tissue plasminogen activator eukaryotic expression vector and its expression in MCF-7 cell line;组织型纤溶酶原激活剂真核表达载体的构建及其在乳癌细胞系MCF-7中的瞬时表达
2.Construction of human tissue plasminogen activator minigene;人组织型纤溶酶原激活剂突变体微小基因的构建
3.Changes and its clinical significance of serum brain-derived neurotrophic factor level and plasma tissue plasminogen activator level in patients with amnestic mild cognitive impairment;遗忘型轻度认知功能损害患者血清脑源性神经营养因子及血浆组织型纤溶酶原激活剂水平变化及其临床意义
5)Tissue type plasminogen activator组织型纤溶酶原激活剂
1.The therapeutic effect and changes of neurofunction deficit score, tissue type plasminogen activator (tPA), plasminogen activator inhibitor (PAI), antithrombin Ⅲ (AT Ⅲ), th.观察两组患者治疗后有效率 ,治疗前后神经功能缺损评分、组织型纤溶酶原激活剂 (tPA)、纤溶酶原激活物抑制剂 (PAI)、抗凝血酶 Ⅲ (AT Ⅲ )、血栓素B2 (TXB2 )及 6 -酮 -前列腺素F1α(6 keto PGF1α)的变化。
2.The releases of tissue type plasminogen activator (t PA) and plasminogen activator inhibitor 1(PAI 1) were determined.方法 培养的人脐静脉血管内皮细胞分别与剂量为 0 ,1,2 ,4 ,8mg/L的蝎毒素IV孵育后 ,测定蝎毒素IV对内皮细胞释放组织型纤溶酶原激活剂 (t PA)、组织型纤溶酶原激活剂抑制物(PAI 1)的影响。
3.The tissue type plasminogen activator (t-PA) is a primary factor in fibrinolysis system.组织型纤溶酶原激活剂(tissue plasminogen activator, t-PA)是纤溶系统的重要因子,外源性t-PA作为溶栓药物的研制在国内外一直是抗血栓药物研发的热点。
6)t-PA组织型纤溶酶原激活剂
1.Fibrin agarose plate assay(FAPA) is a kind of procedure detecting the in vitro fibrinolysis activity of plasminogen activators(PAs) such as urokinase(UK) and tissue-type plasminogen activator(t-PA).在原有的纤维蛋白平板溶圈法 (fibrin agarose plate assay,FAPA)检测系统中引入纤溶酶原 (plasminogen) ,使该法检测组织型纤溶酶原激活剂 (tissue plasminogen activator,t- PA)的灵敏度提高 30倍以上 ,达到 0 。
2.The levels of tissue-plasminogen activator(t-PA) and plasminogen activator inhibitor-1(PAI-1) in blood plasma were detected by ELISA.方法:随机选择72例心病血瘀证患者、20例心病非血瘀证患者与20例健康人,采用ELISA法检测血浆组织型纤溶酶原激活剂(t-PA)及抑制物(PAI-1)。
延伸阅读
重组组织型纤溶酶原激活剂 ,栓体舒药物名称：重组组织型纤溶酶原激活剂英文名：Recombinant Human Tissue-type Plasiminogen别名：重组组织型纤溶酶原激活剂 ,栓体舒 外文名：Recombinant Human Tissue-type Plasiminogen, Actilyse, rTPA药理作用： 本药是一种糖蛋白，可激活纤溶酶原成为纤溶酶。当静脉使用时，本药在循环系统中只有与其纤维蛋白结合后才表现出活性，其纤维蛋白亲和性很高。当和纤维蛋白结合后，本品被激活，诱导纤溶酶原成为纤溶酶，溶解血块，但对整个凝血系统各组分的系统性作用是轻微的，因而不会出现出血倾向。本品不具抗原性，所以可重复使用。 适应症： 用于急性心肌梗塞的溶栓治疗；用于血流不稳定的急性大面积肺栓塞的溶栓疗法；用于急性缺血性脑卒中的溶栓治疗时，必须在脑梗塞症状发生的3小时内进行治疗，且需经影像检查（如CT扫描）除外颅内出血的可能。 用法用量： 除特别处方外，应在症状发生后尽快给药。心肌梗塞 对于发病后6小时内给予治疗的患者，应采取90分钟加速给药法mg静脉推注，其后30分钟内静脉滴注50mg剩余35mg在60分钟内静脉滴注，最大剂量达100mg。对于发病后6-12小时内给予治疗的患者，应采取3小时给药法。10mg静脉推注，其后1小时内脉滴注50mg，剩余40mg在2小时内静脉滴注，最大剂量达100mg。肺栓塞 应在2小时内给予100mg。最常用的给药方法为：10mg在1-2分钟内静脉推注，90mg在2小时内静脉滴注。缺血性脑卒中：推荐剂量为18mg/kg，量大剂量为90mg。先将剂量的10%静脉推入，剩余剂量在超过60分钟时间静脉滴注。 不良反应： 可能出现注射部位出血，如出现严重出血，则应停止溶栓疗法。 注意事项： 最近如有大血管穿刺，应考虑穿刺部位出血的危险。严重肝功能不良的病人，如凝血功能显著下降，则不应使用本药。对妊娠及哺乳的影响迄今尚无在妊娠及哺乳期使用本药的经验。对儿童的影响迄今尚无对儿童使用本药的经验。 注意事项：用药前给予口服抗凝剂会增加出血的危险。与其它纤溶药物合用时，请本酌情减量。 规格： 注射粉剂 20mg*1瓶，50mg*1瓶 类别：抗凝血药和溶血栓药
